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Abstract Relapse occurs frequently after treatment of acute
myeloid leukemia (AML) patients with the FMS-like tyrosine
kinase 3-internal tandem duplication (ITD) mutation. The
availability of immunologic biomarkers to predict patients at
high risk could allow clinicians to accelerate alternative treat-
ments such as stem cell transplantation, immunotherapy, or
novel drugs. We have previously reported that first diagnostic
(FD) ITD+ AML showed immunophenotypic and functional
characteristics of arrested dendritic cell (DC) precursors. In this
study, we show that the high frequency of precursor DCs in 16
FD ITD+ AML samples (Lin−/HLA-DR+/CD11c+/CD123+)
was associated with a lack of terminal DCs (myeloid DCs:
BDCA-1+ or BDCA-3+; plasmacytoid DC: BDCA-2+). We
further evaluated prospectively the peripheral blood complete
remission (CR) samples obtained from 11 ITD+ AML patients
after chemotherapy regarding the frequency of DCs and their
pattern of cytokine production. Whereas the aberrant frequen-
cies of precursor and terminal plasmacytoid DCs resolved
during remission, the myeloid DC compartment did not fully
recover. For an available cohort of patients (n=4) who could
be monitored over a period of >15 months after FD, we
identified IL-10, TNF-α, IL-6, and IL-1β as cytokines pro-
duced by the CR samples at high levels a few months prior to
relapse. Cell-free supernatant of an FD ITD+ AML sample
stimulated monocytes obtained from two healthy donors to
secrete IL-10, TNF-α, IL-6, and IL-1β. Thus, we hypothesize
that ITD+ AML minimal residual disease can act directly as
dysfunctional antigen-presenting cells or indirectly by produc-
tion of factors that convert monocytes into myeloid-derived
suppressor cells secreting cytokines that promote immune
evasion. Monitoring these immunologic biomarkers could
improve prediction of relapse.
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Introduction
Acute myeloid leukemia (AML) is a very heterogeneous
disease and risk stratification has recently been improved by
detection of genetic mutations in samples collected at first
diagnosis (FD) and complete remission (CR) [1]. One of the
most common mutations in AML occurs in the open reading
frame of FMS-like tyrosine kinase 3 (FLT3), which is the
receptor for FLT3-ligand, a cytokine with pivotal function in
dendritic cell (DC) differentiation and in stem cell renewal
[2, 3]. The mutations in the FLT3 receptor occur by point
mutations in the kinase domain or by internal tandem
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duplications (ITD) of the juxtamembrane or tyrosine kinase
domain. These mutations afflict approximately 30 % of the
newly diagnosed AML cases corresponding to a group of
patients at high risk [4, 5]. Once FLT3-ITD is identified,
mutations in other loci can be used to aid in the outcome
prediction (such as NPM1, MLL, N-RAS, and WT1) [5–7].
Novel sensitive approaches to detect leukemia relapse through
next-generation sequencing of mutated hotspots such as
FLT3-ITD and NPM1 are currently in development [8].
Clinical evidence indicates that allogeneic stem cell
transplantation (SCT) of ITD+ AML patients results in the
best survival outcome and is the routine clinical practice for
eligible patients [9]. The mechanistic effects of allo-SCT are
believed to be largely immunological, due to the capacity of
T cells from the donor to mount a curative and long-term
graft-versus-leukemia effect against minimal residual dis-
ease (MRD) [10]. Unfortunately, older patients and patients
without suitable donors are not eligible for allo-SCT and
conventional chemotherapy is the standard of care. For these
patients, novel therapies in clinical development such as
immunotherapy or novel drugs are certainly warranted. In
addition, novel diagnostic approaches such as immune mon-
itoring would potentially impact in the prediction of MRD
immune evasion and relapse.
Dendritic cells play a key role in immune regulation and
function [11, 12]. The DC compartment in cancer patients is
often deregulated, resulting in the accumulation of immature
and/or dysfunctional DCs [13]. We have recently shown that
FD samples of adult ITD+ AML patients contain an aberrant
accumulation of cells with immunophenotypic and functional
characteristics of arrested DCs [14]. Thus, we hypothesize that
residual leukemic ITD+ DCs could potentially affect the dif-
ferentiation of normal DCs of patients during disease recovery
through paracrine mechanisms. In that regard, we evaluated if
cytokines (IL-10, TNF-α, IL-6, and IL-1β) proposed by sev-
eral groups as indicators of a broad range of immunopatho-
logical conditions affecting cancer [15–20] could also serve as
potential biomarkers to predict ITD+ leukemia relapse.
In this study, we prospectively collected samples from 11
ITD+ AML patients treated with standard chemotherapy. Co-
horts of nonresponders, patients who entered remission and
then relapsed or patients with relapse-free survival for
>15 months, were identified. Peripheral blood samples of
ITD− AML patients and healthy donors (HD) were used as
control groups. Kinetic analyses of four ITD+ AML patients
who entered CR but then relapsed between 16 and 24 months
after FD showed a consistent pattern of arrested terminal
differentiation of myeloid DCs and upregulation of IL-10
(an anti-inflammatory cytokine), TNF-α, IL-6, and IL-1β
(pro-inflammatory cytokines) months prior to leukemia re-
lapse. We provided experimental evidence that soluble factors
produced by ITD+ AML stimulated monocytes from healthy
donors to produce IL-10, TNF-α, IL-6, and IL-1β.
Materials and methods
Patient samples
This study was performed in accordance with the declaration
of Helsinki and was approved by the local ethics committee of
the Hannover Medical School. Peripheral blood samples from
adult (18–83 years) AML patients were collected after written
informed consent. Twenty-six ITD+ and 28 ITD− patients, for
whom FD samples were available, were included in this study
(Suppl. Table 1). Peripheral blood mononuclear cells
(PBMCs) were collected from 26 ITD+ patients for up to
24 months after FD and they were grouped according to the
clinical outcome (Suppl. Fig. 1b and Table 1): nonresponders
(NR, no CR after induction therapy, i.e., >5 % blasts in the
BM) and CR. CR patients were split between those who
eventually relapsed >15 months after FD (CR/REL) and those
patients with disease-free survival (CR/DFS, no relapse up to
2 years after FD).
Cytogenetics, FLT3-ITD, and WT1 analyses
Cytogenetic and molecular genetic studies (Table 1 and Suppl.
Table 1) were performed by the German–Austrian Acute
Myeloid Leukemia Study Group at Hannover Medical School
or at the University of Ulm. Blood diagnostic samples were
analyzed for the presence of the ITD mutations in the FLT3
gene by polymerase chain reaction as described previously
[21]. The upregulation of WT1 mRNA levels was used as a
putative approach to predict relapse as previously described
[22]. RNAwas extracted from approximately 5×106 PBMCs
using the Qiagen RNeasy kit according to the protocol of the
manufacturer (Qiagen, Hilden, Germany). Real-time quanti-
tative polymerase chain reaction (RQ-PCR) was performed
with extracted RNA using theWT1 ProfileQuant®-Kit (ELN)
(Ref: PQPP-02-CE) from Ipsogen (Luminy Biotech Enter-
prises, Marseille, France). The RQ-PCR consists of two hold-
ing stages of 1 cycle each at 50 °C for 2 min followed by 95 °C
for 10 min and a cycling stage at 95 °C for 15 s and 60 °C for
1 min (50 cycles) in a StepOnePlus Real-Time PCR system
(Applied Biosystems, Darmstadt, Germany). Standard curves
and fluorescence calculation were performed using the
StepOnePlus Real-Time PCR system and Microsoft Excel
(Microsoft, Germany).
Immunophenotypic analyses of precursor and terminal DCs
PBMCs obtained from patients and healthy volunteers were
isolated by standard density gradient centrifugation using
Ficoll (Biocoll separating solution, Greiner, Bio-One, Germa-
ny) separation and cryopreserved in 90 % FBS and 10 %
DMSO. Progenitor DCs were identified using a commer-
cially available kit (“Peripheral Blood Dendritic Cell
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Detection,” Becton Dickinson BD, San Jose, CA, USA).
The protocol is based on a four-color staining. For the
detection of myeloid and plasmacytoid progenitor DCs, we
used lineage cocktail 1 (FITC) containing monoclonal
antibodies (mABs) against CD3, CD14, CD16, CD19,
CD20, and CD56 as a negative selection, a mAB against
HLA-DR (PerCp, clone L243), a mAB against the CD11c
myeloid DC marker (APC, clone S-HCL-3), and a mAB
against the CD123 plasmacytoid DC marker (PE, clone
95F). Fifty thousand viable cells gated on the forward
scatter (FSC)/side scatter (SSC) were negatively selected
using the lineage markers. The resulting Lin− population
was analyzed for HLA-DR/CD11c (“precursor myeloid
dendritic cells (mDCs)”) or HLA-DR/CD123 (“precursor
plasmacytoid dendritic cells (pDCs)”). Terminal DCs were
identified using a commercially available kit (“Blood
Dendritic Cell Enumeration,” Miltenyi Biotec, Bergisch-
Gladbach, Germany). The protocol is based on a four-
color staining: for mDC1-, a mAB against BDCA-1
(CD1c, PE); for pDC-, a mAB against BDCA-2
(CD303, FITC); and for mDC2 detection, a mAB against
BDCA-3 (CD141, APC). We used a photoaffinity fluores-
cent “dead cell discriminator” (PE-Cy5) and mABs against
CD19 and CD14 to (PE-Cy5) to exclude B cells, mono-
cytes, granulocytes, and dead cells. Fifty thousand viable
cells gated on the FSC/SSC scatter and excluding dead
cells and CD19+/CD14+ cells were analyzed for expression
of BDCA-1 (mDC1), BDCA-2 (pDC), and BDCA-3
(mDC2). Stained cells were analyzed with a FACSCalibur
using CellQuest software (BD, San Jose, CA, USA).
Analyses of cytokine secretion
Cell-free supernatants of PBMC samples obtained from
leukemia patients were obtained by seeding of 1×106 viable
cells in 1 ml of X-vivo medium (Lonza, Belgium) in 12-well
Table 1 Patient characteristics
of ITD+ patient groups NR, CR/
REL, and CR/DFS
NR nonresponders, CR/REL
complete remission followed by
relapse (within 2 years from first
diagnosis), CR/DFS complete
remission and disease-free sur-
vival (for >2 years from first di-
agnosis), FAB French American
British Classification, WBC
white blood cells ×1,000/μl,
NPM1 mutation exon 12
nucleophosmin mutation, WT1
Wilm's tumor 1 gene mutation,
REL relapse, n/a not available
aPatients analyzed for kinetics of
late leukemia relapse and corre-
lation with DC and cytokine
profile
ID Sex FAB WBC Age Karyotype Mutations REL (month)
FLT3 ITD NPM1 WT1
NR
#1 F M4 1.4 57 46, XX + − + −
#2 M M5 n/a 45 Complex + − + −
#3 M M5 119.2 57 n/a + − − −
#4 M sAML 259 67 n/a + − n/a −
#5 M n/a 97 83 n/a + + + −
CR/ REL
#6a M M4 110.1 40 46, XY + + + 18
#7 a F M4 98.1 53 46, XX + + + 16
#8 a F M5 66.7 48 Complex + − + 20
#9 a F M2 69.9 52 46, XX + + + 24
#10 M M5a 56.2 44 46, XY + + n/a 10
#11 M M4 9 24 46, XY + − + 3
#12 F M4 0.4 78 Complex + − + 3
#13 F M5a 107 53 46, XX + + n/a 8
CR/ DFS
#14 F M4 6.3 64 46, XX + + + No REL
#15 F M1 n/a 66 46, XX + + + No REL
#16 M M4 3.1 77 46, XY + + + No REL
#17 M n/a n/a 32 n/a + − n/a No REL
#18 F M2 243 70 46, XX + + n/a No REL
#19 M n/a n/a 40 n/a + + n/a No REL
#20 F M4 45.2 63 46, XX + + + No REL
#21 F M1 3.6 50 46, XX + + + No REL
#22 M n/a 12 40 46, XY + − + No REL
#23 F M3 n/a 65 APL + − n/a No REL
#24 F M5 n/a 61 46, XX + − n/a No REL
#25 M M6 5.9 18 46, XY + + n/a No REL
#26 M M5b n/a 67 46, XY + + n/a No REL
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plates (TPP, Switzerland), incubated for 24 h at 37 °C and
5 % CO2, collected, centrifuged to remove cells and debris,
and cryopreserved at −80 °C. Luminex® analyses were
performed with a Cytokine Human 14-Plex Panel
(Millipore, Schwalbach, Germany) for analyses of IL-10,
TNF-α, IL-6, and IL-1β. As controls, supernatants obtained
from PB samples obtained from four healthy donors were
included in the analyses. Cytokine standards supplied by the
manufacturer were run on each plate together with the test
samples. Samples were treated accordingly to manufac-
turer's instructions. For cytokine detection, data were ac-
quired on a Luminex-200 System and analyzed with the
Xponent software v.3.0 (Invitrogen).
Treatment of CD14+ monocytes with AML supernatant
The cell culture supernatant collected from one of the FD
samples in the study (CR/REL patient #6) as described
above was filtered with 0.2 μM and diluted with X-vivo
medium at dilutions of 1:3 and 1:9. CD14+ monocytes were
isolated from the leukapheresis of healthy donors using
CD14 microbeads (Miltenyi, Germany). The isolated
CD14+ monocytes were seeded at a density of 5×106 cells
per well and were cultured in X-vivo medium or with
diluted 2-ml AML supernatants in a six-well plate. The
plates were incubated at 37 °C for 3 days. At the end of
the incubation period, the cell viability and monocyte purity
were assessed by flow cytometric analyses of 7AAD and
CD14. The cell supernatants were collected and the cytokine
profile was analyzed by Luminex® as described above.
Results
FD samples of ITD+ AML patients showed a more
pronounced alteration of the dendritic cell pattern
in comparison to FD samples of ITD− AML patients
We had previously reported that FD samples of ITD+ pa-
tients presented with an accumulation of Lin−/HLA-DR+
cells that co-expressed the DC markers CD11c and/or
CD123. These leukemic DCs contained ITD mutations and
could be driven to differentiate into mature mDCs or pDCs
in vitro upon culture with cytokines, but they were not fully
capable of secreting several cytokines [14]. We therefore
deduced that CD11c+, CD123+, and CD11c+/CD123+ leu-
kemic DCs were arrested in the dendritic cell differentiation
pathway and that CD11c+ and CD123+ should be rather
considered as DC precursor markers. In order to assess the
frequencies of mature DCs in leukemia samples, we there-
fore used a second immunophenotypic panel. Here, terminal
DCs were defined as mDC1 (BDCA-1+), pDC (BDCA-2+),
or mDC2 (BDCA-3+). Validation of the immunophenotypic
analyses was performed with cryopreserved/thawed PBMC




A) Analyses of DC precursors at FD
ns p <0,05 p <0,05
nsnsns
Fig. 1 FD samples of ITD+
AML patients (n=16) showed a
more pronounced alteration of
the dendritic cell pattern in
comparison with the FD
samples of ITD− AML patients
(n=22). a Frequencies of
precursor DCs. b Frequencies
of terminal DCs. Single
asterisk: significantly higher
than HD (p<0.05). Double
asterisk: significantly lower
than HD (p<0.05). [The dotted
line is showing the average
values for HD]
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obtained from nine healthy control donors. For both types of
immunophenotypic analyses, we observed a higher frequen-
cy of mDCs (approximately 0.4 %) compared to pDCs
(approximately 0.2 %) (Suppl. Fig. 1a). The frequencies of
mixed lineage mDC/pDCs (CD123+/CD11c+) and of mDC2
were quite low (below 0.1 %). Using the same staining
procedures, we examined FD-cryopreserved samples of
ITD+ and ITD− patients who were diagnosed and treated at
the Hannover Medical School. We compared the FD sam-
ples of 16 ITD+ and 22 ITD− patients, who eventually
entered CR. The cohorts were reasonably similar in terms
of gender distribution, age, WBC counts, NPM1 mutation
frequency, FAB types, and cytogenetics (Suppl. Table 1). In
contrast to the homogeneous frequencies of DCs in PBMC
samples obtained from HD (0−0.83 %), FD samples from
ITD+ and ITD− patients showed a high variability in the
frequencies of precursor DCs, ranging from 0 to 71 %
(Fig. 1a and Suppl. Figs. 1a and 2a). We observed the
previously reported accumulation of mDC/pDC precursors
(CD123+/CD11c+) in FD obtained from ITD+ patients
(Fig. 1a and Suppl. Fig. 2a). The frequencies of mDC/pDC
precursors were significantly increased in both ITD+ (p=
0.0065) and ITD− (p=0.0077) FD patient samples compared
to HD PBMCs. Notably, the accumulation of mDC/pDC
precursors was significantly higher in the FD of ITD+ pa-
tients compared to the FD of ITD− patients (mDC: p=0.046;
pDC: p=0.049). The same samples demonstrated almost
complete lack of terminal mDC1s (BDCA-1+) and pDCs
(BDCA-2+) (Fig. 1b and Suppl. Fig. 2b). Of note, signifi-
cantly lower frequencies of terminal mDC1 (p<0.0001) and
pDC (p<0.0001) were found in FD samples of ITD+ pa-
tients compared to HD, whereas the frequencies of terminal
DCs in FD samples of ITD− were not significantly affected
(Fig. 1b). Thus, these results fully corroborated with our
previous findings using another AML cohort, showing that
the ITD mutation in AML is correlated with the accumula-
tion of mDC/pDC precursors. Furthermore, these leukemic
ITD+ DC precursors did not display the terminally differen-
tiated DC immunophenotype. These findings combined un-
derscore the notation that ITD+ AML corresponds to an
arrested DC lineage malignancy.
FD samples obtained from ITD+ NR patients secreted higher
levels of IL-10 and stress cytokines in vitro in comparison
to CR patients
IL-10 is produced mostly by macrophages and myeloid DCs
and is generally regarded as an anti-inflammatory cytokine
exerting several effects in immunomodulation of the cancer
microenvironment and cancer progression [17]. Direct inhi-
bition of myeloid DC differentiation mediated through IL-
10 and IL-6 was proposed to induce a potentially
immunocompromising microenvironment in cancer patients
[23]. IL-6, TNF-α, and IL-1β are predominantly secreted by
activated monocytes and macrophages and play a central
role in innate inflammatory events. Remarkably, the neuro-
endocrine stress system in human beings is also triggered
via soluble factors such as IL-6, TNF-α, and IL-1β, hereto-
fore named “stress cytokines” [17, 24]. Therefore, we pro-
posed to evaluate whether FD containing ITD+ leukemic
cells would show particular patterns of expression of IL-10
and/or stress cytokines. FD samples obtained from NR
patients showed higher levels of production of all stress
cytokines compared with PBMC of HD, whereas IL-10
levels were similar (Fig. 2). On the other hand, FD samples
obtained from ITD+ CR patients (CR/REL and CR/DFS)
showed lower levels of secreted IL-10, TNF-α, IL-6, and
IL-1β than PBMCs of HD controls (Fig. 2). Thus, compared
with the DC immunophenotypic analyses of ITD+ AML
showing a more uniform pattern, the cytokine secretion
pattern was more heterogeneous. These findings suggested
that either the ITD+ leukemic cells from NR patients secret-
ed cytokines in a different pattern than cells obtained from
CR/REL and CR/DFS, or that bystander cells contained in
FD samples of NR patients could be responsible for the
secretion of the cytokines.
CR samples obtained from ITD+ AML patients showed
lower recovery of myeloid DCs compared with samples
obtained from ITD-AML patients
Low DC frequencies in leukemia patients after initial treat-
ment and/or HSCT have been associated with relapse and a
poor outcome [25, 26]. Therefore, we compared the fre-
quencies of precursor and terminal DCs in samples obtained
from ITD+ (n=11) and ITD− (n=13) patients in CR (Suppl.
Fig. 1b and Table 1). During CR, the mDC/pDC precursor
population disappeared in both the ITD+ and ITD− cohorts
(Fig. 3a). ITD+ CR patients showed a trend towards lower
frequencies of terminal myeloid DCs (mDC1, p=0.057;
mDC2, p=0.0912) in comparison to HD (Fig. 3b). These
findings suggested that the aberrant DC patterns observed at
ITD+ AML diagnosis tended to normalize during CR, but
did not return to the normal situation observed in healthy
individuals. Thus, despite of this modest alteration in DC
frequency, we could not identify a major aberration in CR
samples of ITD+ AML patients as a whole.
Kinetic analyses of CR samples of ITD+ patients showed
persistent accumulation of mDC/pDC precursors
and a decline in the levels of terminal mDCs who relapsed
after 15 months
We chose four patients who experienced leukemia relapse
within 2 years after FD (see Table 1, CR/REL patients 6, 7,
8, and 9) for performing kinetic analyses. PBMC samples
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were collected five times sequentially after FD (every
3 months and up for 15 months). The frequencies of pre-
cursor mDCs and pDCs normalized during the first 6 months
of CR (although always lower than healthy controls), but
then decreased continuously until 15 months (Fig. 4a). The




Fig. 2 FD samples obtained
from NR ITD+ AML patients
(n=4) secreted higher levels of
stress cytokines in vitro in
comparison with patients who
entered CR (n=7). NR
nonresponders (n=4), CR/REL
complete remission followed by
relapse (<2 years; n=4),
CR/DFS complete remission
and disease-free survival
(>2 years) (n=3), HD healthy
donors (n=4). Single asterisk:
significantly lower than HD
p<0.05. [Detection level for







A) Analyses of DC precursors at CR
B) Analyses of terminally differentiated DCs at CR
Fig. 3 CR samples obtained
from ITD+ AML patients (n=
11) showed suboptimal
recovery of myeloid DCs
compared with samples
obtained from ITD− AML
patients (n=13). a
Normalization in the
frequencies of precursor DCs. b
Trend for lower frequencies of
terminal mDCs. [The dotted
line is showing the average
values for HD]
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during CR, but was nevertheless still detectable throughout
the observation period (Fig. 4a). The frequencies of terminal
mDC1s were always lower compared to HD controls,
whereas terminal mDC2s returned to normal levels at
15 months (Fig. 4b). The frequencies of terminal pDCs did
not reveal significant fluctuations during CR (Fig. 4b). Al-
together, these results showed that for patients who relapsed,
alterations in mDC frequency persisted throughout the re-
mission period. Notably, both precursor and terminally dif-
ferentiated mDC tended to disappear prior to relapse.
IL-10 and stress cytokines secreted by CR/REL samples
were observed as a later event, preceding relapse
We had observed that secretion of IL-10, TNF-α, IL-6, and
IL-1β cytokines in FD samples of ITD+ nonresponder pa-
tients was higher than for patients who entered CR (Fig. 2),
but we could not discern if the leukemic cells or possible
bystander cells were producing the cytokines. IL-10 and
stress cytokines have been linked with the occurrence of
myeloid-derived suppressor cells (MDSCs), which can hin-
der DC development from myeloid precursor cells [27–29].
Since CR leukemic cells were not detectable in PBMC
samples by morphology, we investigated if non-leukemic
cells contained in the PBMC samples might lead to aberrant
cytokine production. We used samples from the same four
CR/REL patients described above for the cytokine secretion
patterns at earlier (6 months, Fig. 5a) and later time points
(12 months, Fig. 5b) after FD. As controls, we included
samples obtained from three CR/DFS patients and four HD
in the analyses. At 6 months after FD, IL-10 secretion by
PBMCs of CR/REL samples was significantly lower than
for samples from CR/DFS patients and HD, but the levels of
the stress cytokines were comparable (Fig. 5a). Yet, at
12 months after FD, there was a trend for higher production
of all stress cytokines in CR/REL samples in comparison
with CR/DFS patients and HD samples (Fig. 5b). Neverthe-
less, results correlated with the lower frequencies of mDCs
observed in CR/REL patients 12 months after FD (Fig. 4)
suggesting that increased production of stress cytokines by
cells contained in the PBMC samples was linked to de-
creased mDC differentiation. Since the PBMC samples at
12 months did not show detectable leukemic blasts, this
finding underscored our hypothesis that other cells, such
as myeloid precursor cells or myeloid-derived suppressor
cells, could be implicated in the secretion of the cytokines.
Soluble factors produced by the ITD+ FD samples can
increase viability and stimulate monocytes to secrete
IL-10 and stress cytokines
It was previously shown that cell supernatants obtained
from leukemic cells inhibited DC differentiation ex vivo,
promoted by recombinant cytokines [30]. We set up similar
assays with cell culture supernatants obtained from an ITD+
FD sample and from a leukemic cell line. However, we did
B) Analyses of terminally differentiated DCs prior to relapse





Fig. 4 Kinetic analyses of DC
patterns during CR of ITD+
AML patients (n=4) showed
persistent accumulation of
mDC/pDC precursors and a
decline in the levels of terminal
mDC1 prior to relapse. a
Frequencies of precursor DCs at
0, 3, 6, 9, 12, and 15 months. b
Frequencies of terminal DCs at
0, 3, 6, 9, 12, and 15 months.
Single asterisk: significantly
higher than HD (p<0.05).
Double asterisk: significantly
lower than HD (p<0.05). [The
dotted line is showing the
average values for HD]
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not observe inhibition of DC differentiation (data not
shown). We thus evaluated the effects of leukemic cell
supernatants on CD14+ monocytes, which are myeloid pre-
cursors of mDC. Cell supernatant collected from an ITD+
FD sample (obtained from CR/REL patient #6 (Table 1))
was used as conditioned media for the culture of CD14+
monocytes obtained from two healthy donors (enriched to
90–95 % purity with immunoconjugated magnetic beads).
The experiments were performed using 1:3 and 1:9 leuke-
mic supernatant dilutions in order to evaluate a possible
dose-dependent effect. A mock baseline control was run in
parallel. The monocytes were collected after 3 days of
culture and analyzed for viability and purity, while the
supernatants were analyzed for cytokine production. For
the two independent experiments, FD leukemia supernatant
at 1:3 dilution doubled the viability of monocytes compared
to the 1:9 dilution or the mock control (Fig. 6a). Correlating
with the increased monocyte viability, the leukemia super-
natant (1:3 dilution) induced the secretion of IL-10, TNF-α,
IL-6, and IL-1β in both experiments (Fig. 6b).
Discussion
Deregulated dendropoiesis and DC dysfunction have been
acknowledged in recent years to trigger immune evasion
A) 6 months after FD B) 12 months after FD
* #
Fig. 5 Secretion of stress
cytokines by PBMC samples of
CR/REL samples (n=4) was
observed as a later event
(12 months after FD), yet
several months prior to relapse.
CR/DFS patients (n=3) were
not significantly different to
healthy donors (HD, n=4). a
Cytokines secreted at 6 months
after FD, comparing CR/REL,
CR/DFS and HD. b Cytokines
secreted at 12 months after FD,
comparing CR/REL, CR/DFS,
and HD. Single asterisk:
significantly lower than
CR/DFS (p<0.05). Number
sign: trend for lower secretion
compared to HD (p=0.0988).
[Detection level for cytokines is
3.2 pg/ml]
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and tolerance induction against cancer [13, 31, 32]. Incom-
plete regeneration of DC populations in leukemia patients
after stem cell transplantation has also been described in the
literature as a negative prognostic factor [25, 26]. We have
previously demonstrated that the presence of the ITD muta-
tion in AML was correlated with an aberrant accumulation
of cells with hallmarks of arrested dendritic cells [14]. We
hypothesized that constitutive signaling through FLT3-ITD
could arrest MRD leukemic dendritic cell precursors in an
immature stage. In this study, we confirmed and extended
our previous observation and hypothesis, as leukemic ITD+
DC did not show expression of molecules used routinely as
markers for quantification of differentiated myeloid or
plasmacytoid DC in peripheral blood (BDCA-1, BDCA-2,
and BDCA-3).
Furthermore, we proposed to evaluate the patterns of
dendritic cell lineages and of a subset of immunomodulatory
cytokines (IL-10, TNF-α, IL-6, and IL-1β) during the
course of ITD+ leukemia. We obtained samples from pa-
tients treated with conventional induction/consolidation
chemotherapy, from the first diagnosis to eventual relapse.
Our results indicated an incomplete regeneration of the
myeloid dendritic cell compartment in ITD+ leukemia pa-
tients, which was aggravated prior to relapse (Suppl. Fig. 3).
Notably, the decreased frequencies of mDCs in PBMC sam-
ples obtained prior to relapse were correlated with increased
secretion of IL-10 and stress cytokines (TNF-α, IL-6, and
IL-1β) in comparison to samples obtained from patients who
did not relapse. The fact that leukemic cells could not be



































Effects of ITD+ AML supernatant on monocyte viability and             
purity
Effects of ITD+ AML supernatant on secretion of 
cytokines by monocytes
Fig. 6 Soluble factors
produced by ITD+ AML
PBMCs (patient #6) can
increase viability and stimulate
monocytes to secrete stress
cytokines. a ITD+ AML
supernatant increases the
viability of monocytes in vitro,
as shown on day 3 of culture,
and preserves the expression of
CD14. b ITD+ AML
supernatant stimulates
monocytes to produce stress
cytokines after 3 days of
co-culture. [Detection level for
cytokines is 3.2 pg/ml]
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non-leukemic cells were involved with secretion of these
cytokines. In order to experimentally test this, we demonstrat-
ed in a 3-day assay that cell-free supernatants obtained from
an ITD+ diagnostic sample could activate monocytes obtained
from healthy donors to secrete IL-10, TNF-α, IL-6, and IL-
1β. Based on these observations, we hypothesize that sup-
pression of dendropoiesis during remission of ITD+ leukemia
is mediated by soluble factors (produced by minimal residual
leukemia or by the leukemia microenvironment) that activate
myeloid cells (such as monocytes) to produce IL-10, IL-6,
TNF-α, and IL-1β. These cytokines in turn could deregulate
the differentiation and maturation of myeloid DC (Fig. 7).
IL-6 was defined as a crucial factor for tumor survival
and immune evasion, i.e., via induced secretion of IL-10 by
regulatory T cells, which effectively suppresses adaptive
immune responses towards tumor antigens [33] and induces
proliferation of immature myeloid cells [34]. The combina-
tion of IL-6 and its inducers TNF-α and IL-1β [35] pro-
motes tumor growth and survival in cancer patients through
maintenance of chronic inflammation and induction of a
tumor-supporting microenvironment [19, 36].
Prior to our work, supernatants of FD leukemia samples
containing IL-6 and IL-10, TNF-α, and IL-1β were shown
to trigger a block in DC differentiation in vitro [30]. These
results corroborate in part with ours, as we observed high
levels of these cytokines only in FD samples of patients who
did not enter remission. In our experimental setting, the FD
leukemia supernatants did not block ex vivo differentiation
of conventional myeloid DC (grown in the presence of GM-
CSF and IL-4, results not shown). Nevertheless, we were
able to show an effect of the FD leukemia supernatants on
monocyte viability as a feedback loop for production of
these same cytokines. It is important to note that IL-6 and
IL-10, TNF-α, and IL-1β have been implied in the genera-
tion of the MDSCs, which are commonly found in cancer
patients [27–29, 37, 38]. MDSCs are a heterogeneous group
of immature myeloid cells arrested in an early differentiation
step towards becoming a DC and defined by their immuno-
suppressive capacities [38–40], which include direct
inhibition of tumor-reactive T cells [27, 41]. Interestingly,
the ITD mutation itself was shown to be implied in certain
regulatory mechanisms, i.e., by induction of increased reac-
tive oxygen species production [42], which is regulating a
major mechanism of immune suppression in cancer as in-
duced by MDSCs [37].
Noteworthy, a previous study evaluated serum levels of
TNF-α, IL-6, and IL-10, in diagnostic samples obtained
from patients with AML or high-risk myelodysplastic syn-
dromes. Lower TNF-α levels were found to significantly
correlate with better performance status, whereas the other
cytokines were not found to be predictive of clinical out-
comes [43]. Blockage of TNF-α is already used as standard
treatment in various autoimmune diseases [35], whereas
clinical trials to evaluate blockage of IL-6 and IL-1β in
inflammatory diseases and cancer are ongoing [35, 44–46].
Thus, evaluation of novel immunomodulatory approaches
like these may be also warranted for improving survival of
ITD+ AML patients.
In conclusion, lack of mature mDCs in ITD+ FD
patient samples in combination with the incomplete re-
generation of mDCs during remission and higher secre-
tion of IL-10 and stress cytokines (TNF-α, IL-6, and IL-
1β) in patients who relapsed strengthen the hypothesis of
immunomodulatory changes during the course of ITD+
AML relapse. These events are likely to be linked with a
“subverted dendropoiesis” and induction of MDSC in these
leukemia patients (Fig. 7). Thus, clinical monitoring of PBMC
samples of ITD+ patients during remission in order to enu-
merate the DC profile and to detect the secretion of IL-10 and
stress cytokine levels as well as the occurrence of MDSCs
might serve as immunologic biomarkers to provide additional
approaches for disease staging.
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